Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Outcomes in the Early Use of Vasopressin in Septic Shock
2023-509071-16-00Phase 4Authorised
- Sponsor
- Azienda USL di Bologna
- Start
- Mar 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of vasopressin in septic shock (2 arms), sponsored by Azienda USL di Bologna. Planned start Mar 2024; status: authorised.
02
Drugs
vasopressin
03
Conditions
septic shock
Beyond the preview
Go deeper on 2023-509071-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509071-16-00.